EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Antibody and B‐Cell Responses to PHH‐1V81 XBB.1.16‐Adapted SARS‐CoV‐2 Booster Vaccination Are Associated With Variant Neutralization

Cèlia Torres, Alfons Jiménez, Meritxell Deulofeu, Antoni Prenafeta, Carlota Dobaño iD, Gemma Moncunill, Laura Ferrer, Luis M Molinos-Albert iD

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Cèlia Torres und 7 weiteren Autor:innen. Beteiligte Einrichtung: ISGlobal, Barcelona, Spain. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, Antibodies, Viral, B-Lymphocytes. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was supported by HIPRA..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune escape by SARS‐CoV‐2 emerging variants jeopardizes vaccine effectiveness, necessitating new immunization strategies. Here, we assessed the antibody B‐cell response in 40 individuals receiving either the PHH‐1V81 XBB.1.16‐ or BNT162b2 XBB.1.5‐adapted vaccine boosters. Both immunizations significantly increased ancestral‐reactive B cells cross‐recognizing the vaccine variant. Notably, XBB.1.16 cross‐reactive B cells were associated with neutralizing responses, reinforcing the potential of PHH‐1V81 as a strong boosting candidate against emerging variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralB-LymphocytesCOVID-19COVID-19 VaccinesHumansImmunization, SecondaryBNT162 VaccineMaleFemaleMiddle AgedAdultCross ReactionsAged

Stichwörter der Autor:innen

B cellsSARS‐CoV‐2infectious diseasesneutralizing antibodiesvaccines

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesBNT162 Vaccine

Autor:innen und Institutionen

  • ISGlobal, Barcelona, Spain.
  • Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
  • HIPRA, Amer, Girona, Spain.
  • CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Carlota Dobaño, Luis M Molinos-Albert

Förderung

  • This study was supported by HIPRA.

Zitieren

APA

Torres, C., Jiménez, A., Deulofeu, M., Prenafeta, A., Dobaño, C., Moncunill, G., Ferrer, L., & Molinos-Albert, L. M. (2025). Antibody and B‐Cell Responses to PHH‐1V81 XBB.1.16‐Adapted SARS‐CoV‐2 Booster Vaccination Are Associated With Variant Neutralization. Journal of Medical Virology. https://doi.org/10.1002/jmv.70583

Vancouver

Torres C, Jiménez A, Deulofeu M, Prenafeta A, Dobaño C, Moncunill G, et al. Antibody and B‐Cell Responses to PHH‐1V81 XBB.1.16‐Adapted SARS‐CoV‐2 Booster Vaccination Are Associated With Variant Neutralization. Journal of Medical Virology. 2025. doi:10.1002/jmv.70583

BibTeX
@article{Torres2025,
  author = {Torres, Cèlia and Jiménez, Alfons and Deulofeu, Meritxell and Prenafeta, Antoni and Dobaño, Carlota and Moncunill, Gemma and Ferrer, Laura and Molinos-Albert, Luis M},
  title = {Antibody and B‐Cell Responses to PHH‐1V81 XBB.1.16‐Adapted SARS‐CoV‐2 Booster Vaccination Are Associated With Variant Neutralization},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70583}
}
Kostenlos starten →